



Express Mail Label: EV53202760US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): FRIDMAN, Herve W.

Group Art Unit: 1646

Application No.: 09/980,545

Examiner: Xiaozhen Xie

Filed: 03/27/2000

Attorney Docket No. : SF0941K1US

For: COMPOSITIONS AND METHODS FOR
TREATING CELL PROLIFERATION
DISORDERS

X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: **AMENDMENT**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R §1.56, it is requested that the documents listed on the accompanying Forms PTO/SB.08a and 08b be considered and made record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) _____ filed _____, respectively. Since the Examiner is believed to have ready access to the cited U.S. parents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application, **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE), **or**
- ☒ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.


☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **19-0365**,

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case.

Document AC, DE 298 20 466U1, is in a foreign language. The undersigned does not know whether this document is relevant to the claims in the present application. Document AC was cited in the International Search Report, a copy which is filed herewith and listed as document AD.

For listed documents for which the month in which the document was published is not provided, the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION



By:

Name: Grant E. Red
Reg. No.: 41,264
Attorney of Record
Telephone No.: (908) 298-5067

Dated: **February 23, 2006**
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388



Express Mail Label: EV532027670US

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

Application Number	09/980,545
Filing Date	03/27/2000
First Named Inventor	FRIDMAN, Herve W.
Art Unit	1646
Examiner Name	Xiaozhen Xie
Attorney Docket Number	SF0941K1 US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AA	WO 97/04097	02/06/1997	PCT		
	AB	WO 99/14240	03/25/1999	PCT		
	AC	DE 298 20 466 U1	05/20/1999	GERMANY		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label: EV532027670US

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Complete if Known

Application Number	09/980,545
Filing Date	03/27/2000
First Named Inventor	FRIDMAN, Herve W.
Art Unit	1646
Examiner Name	Xiaozhen Xie
Attorney Docket Number	SF0941K1 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	International Search Report for PCT/US 00/08081 - 6 Pages	
	AE	Tartour et al., IL17, a T cell derived cytokine which promotes the in vivo growth of cervical tumors in nude mice, 6001 Chemical Abstracts 39, No. 4447, p. 693, XP -002129053 (March 1998)	
	AF	Wakasugi et al., Tumorigenicity of cancer cells transfected with IL-17 gene in vivo, 6001 Chemical Abstracts 39, No. 37, p 6, XP-002129054 (March 1998)	
	AG	Tartour, et al., Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of Human Cervical Tumors in Nude Mice, Cancer Research, Vol. 59:3698-3704 (August 1999)	
	AH	Benchetrit et al., Interleukin-17 inhibits tumor cell growth by means of a T-Cell dependent Mechanism, Blood, Vol. 99:6, 2114-2121 (March 2002)	
	AI	Pages et al, Control of tumor development by intratumoral cytokines, Immunology Letters, Vol. 68:135-139 (May 1999)	
	AJ	Fossiez et al., Interleukin-17, Intern. Rev. Immunol. 16:541-551 (May 1998)	
	AK	Laan et al., Neutrophil Recruitment by Human IL-17 Via C-X-C Chemokine Release in the Airways, Journal of Immunology 162: 2347-2352 (February 1999)	
	AL	Antonyamy et al., Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the functional Differentiation of Dendritic Cell Progenitors, Journal of Immunology 162:577-584 (January 1999)	
	AM	Spriggs, Interleukin-17 and Its Receptor, Journal of Clinical Immunology Vol. 17:5, 366-369 (September 1997)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number

09/980,545

Filing Date

11/15/2001

First Named Inventor

FRIDMAN, Herve W.

Art Unit

1646

Examiner Name

Xiaozhen Xie

Attorney Docket Number

SF0941K1 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AN	Yao, et al., Human IL-17: A Novel Cytokine Derived from T Cells, Journal of Immunology 155:5483-5486 (December 1995)	
	AO	Schiffman et al., The Epidemiology of Cervical Carcinogenesis, Cancer 76:1888-1901 (1995)	
	AP	Eustace et al., Interleukin-6(IL-6) Functions as an Autocrine Growth Factor in Cervical Carcinomas in Vitro, Gynecol. Oncol. 50:15-19 (1993)	
	AQ	Woodworth et al, Comparative Lymphokine Secretion by Cultured Normal Human Cervical Keratinocytes, Papillomavirus-Immortalized, and Carcinoma Cell Lines, Am. J. Pathol. 142:1544-1555 (May 1993)	
	AR	Singh et al., Expression of Interleukin 8 Correlates with the Metastatic Potential of Human Melanoma Cells in Nude Mice, Cancer Research 54:3242-3247 (June 1994)	
	AS	Attur et al, Interleukin-17 Up-Regulation of Nitric Oxide Production In Human Osteoarthritis Cartilage, Arthritis & Rheumatism 40:1050-1053 (June 1997)	
	AT	Iglesias et al., Interleukin-6 and Interleukin-6 Soluble Receptor Regulate Proliferation of Normal, Human Papillomavirus-Immortalized, and Carcinoma-Derived Cervical Cells in Vitro, Am. J. Patol 146:944-952 (1995)	
	AU	Fridman et al., Cytokines and Cell Regulation, Molec. Aspects Med. 18:1-90 (1997)	
	AV	Vink et al., Mouse Plasmacytoma Growth In Vivo: Enhancement by Interleukin 6 (IL-6) and Inhibition by Antibodies Directed against IL-6 or Its Receptor, J. Exp. Med. 172:997-1000 (1990)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number

09/980545

Filing Date

03/27/2000

First Named Inventor

FRIDMAN, Herve W.

Art Unit

1646

Examiner Name

Xiaozhen Xie

Attorney Docket Number

SF0941K1 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AW	Durandy et al., Role of IL-6 in Promoting Growth of Human EBV-Induced B-Cell Tumors in Severe Combined Immunodeficient Mice, J. Immunol. 152:5361-5367 (1994)	
	AX	Bataille et al., Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma, Blood 86:685-691 (July 1995)	
	AY	Schadendorf et al., IL-8 Produced by Human Malignant Melanoma Cells in Vitro Is an Essential Autocrine Growth Factor, J. Immunol. 151:2667-2675 (September 1993)	
	AZ	Rouvier et al., CTLA-8, Cloned from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene, J. Immunol. 150: 5445-5456 (1993)	
	BA	Fossiez et al., T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hematopoietic Cytokines J. Exp. Med 183:2593-2603 (June 1996)	
	BB	Mittrucker et al., CD2-mediated Autocrine Growth of Herpes Virus Saimiri-transformed Human T Lmphocytes, J. Exp. Med 176:909-913 (September 1992)	
	BC	Biesinger et al., Stable Growth Transformation of Human T Lymphocytes by Herpesvirus Saimiri, Proc. Natl. Acad. Sci. U.S.A. 89:3116-3119 (1992)	
	BD	Yao et al., Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor, Immunity 3:811-821 (December 1995)	
	BE	Chabuad et al., Enhancing Effect of IL-17 on IL-1 Induced IL-6 and Leukemia Inhibitory Factor Production by Rheumatoid Arthritis Synoviocytes and Its Regulation by Th2 Cytokines1, J. Immunol 161:409-414 (1998)	
	BF	Shalom-Barak et al., Interleukin-17-induced Gene Expression in Articular Chondrocytes Is Associated with Activation of Mitogen-activated Protein Kinases and NF-kB*, J. Biol. Chem 273:27467-27473 (October 1998)	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number

09/980545

Filing Date

03/27/2000

First Named Inventor

FRIDMAN, Herve W.

Art Unit

1646

Examiner Name

Xiaozhen Xie

Attorney Docket Number

SF0941K1 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BG	Jovanovic et al., IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-B and TNF-(alpha), by Human Macrophages, J. Immunol. 160:3513-3521 (1998)	
	BH	Tartour et al., Analysis of Interleukin 6 Gene Expression in Cervical Neoplasia Using a Quantitative Polymerase Chain Reaction Assay: Evidence for Enhanced Interleukin 6 gene Expression in Invasive Carcinoma, Cancer Research 54:6243-6248 (December 1994)	
	BI		
	BJ		
	BK		
	BL		
	BM		
	BN		
	BO		
	BP		

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.